

Causal Evaluation of Laboratory Markers in Type 2 Diabetes on Cancer and Vascular Diseases Using Various Mendelian Randomization Tools

Heejin Jin^{1,2}, Sanghun Lee^{3*}, Sungho Won^{1,4,5*}

¹Department of Public Health Sciences, Seoul National University, Seoul, Republic of Korea

²Medical Research Collaborating Center, Department of Biostatistics, Seoul National University Boramae Hospital, Seoul, Republic of Korea

³Department of Medical Consilience, Graduate School, Dankook University, Yongin-si, Republic of Korea

⁴Institute of Health and Environment, Seoul National University, Seoul, South Korea

⁵RexSoft Corp, Seoul, South Korea

Abstract

Multiple studies have demonstrated the effects of type 2 diabetes (T2D) on various human diseases; however, most of these were observational epidemiological studies that suffered from many potential biases including reported confounding and reverse causations. In this article, we investigated whether cancer and vascular disease can be affected by T2D-related traits, including fasting plasma glucose (FPG), 2-h postprandial plasma glucose (2h-PG), and glycated hemoglobin A1c (HbA1c) levels, by using Mendelian randomization (MR). The summary statistics for FPG, 2h-PG, and HbA1c were obtained through meta-analyses of large-scale genome-wide association studies that included data from 133,010 non-diabetic individuals from collaborating Meta-Analysis of Glucose and Insulin related traits Consortium studies. Thereafter, based on the statistical assumptions for MR analyses, the most reliable approaches including inverse-variance-weighted (IVW), MR-Egger, MR-Egger with a simulation extrapolation (SIMEX), weighted median and MR-Pleiotropy RESidual Sum and Outlier (MR-PRESSO) methods were applied to identify traits affected by FPG, 2h-PG, and HbA1c. We found that coronary artery disease is affected by FPG, as per the IVW [log odds ratio (logOR): 0.21; $P=0.012$], MR-Egger (SIMEX) (logOR: 0.22; $P=0.014$), MR-PRESSO (logOR: 0.18; $P=0.045$), and weighted median (logOR: 0.29; $P<0.001$) methods, but not as per the MR-Egger (logOR: 0.13; $P=0.426$) approach. Furthermore, low-density lipoprotein cholesterol levels are affected by HbA1c, as per the IVW (beta (B): 0.23; $P=0.015$), MR-Egger (B: 0.45; $P=0.046$), MR-Egger (SIMEX) (B: 0.27; $P=0.007$), MR-PRESSO (B: 0.14; $P=0.010$), and the weighted median (B: 0.15; $P=0.012$) methods. Further studies of the associated biological mechanisms are required to validate and understand the disease-specific differences identified in the T2D-related causal effects of each trait.

1 Introduction

Type 2 diabetes (T2D) is characterized by high blood sugar, insulin resistance, and a relative lack of insulin and represents a common metabolic disorder worldwide. In its early stage, T2D is easy to ignore due to the lack of symptoms; however, chronic or poorly controlled T2D leads to eventually disabling or life-threatening complications. Numerous epidemiological studies have consistently demonstrated increased risks of cancer, vascular disease, nerve damage, and poor health-related outcomes in T2D patients (De Vegt et al., 1999; Laakso, 1999; Tsilidis et al., 2015), resulting in a shorter life expectancy (Collaboration, 2011). The main T2D-related complications reported in large-scale epidemiological studies tend to be malignant solid tumors (Johnson et al., 2012) and cardiovascular disease, including ischemic heart disease and stroke (Nesto, 2001; Bax et al., 2007; Gleissner et al., 2007; Young et al., 2009). However, the causal relationship between T2D and diverse health-related outcomes needs to be investigated and compared.

Fasting plasma glucose (FPG) levels ≥ 126 mg/dL or post-challenge 2-h plasma glucose (2h-PG) levels ≥ 200 mg/dL in a 75-g 2-h oral glucose tolerance test (2h-OGTT) have been used as diagnostic criteria for T2D. Additionally, hemoglobin A1c (HbA1c) levels $\geq 6.5\%$ were added to these diagnostic criteria in 2010 (Gavin III et al., 1997; Association, 2010). The three tests (FPG, 2h-PG, and HbA1c) are dependent on blood glucose metabolism status. Specifically, FPG assesses the state of stable sugar levels in the body following a temporary increase in externally administered sugar. The 2h-OGTT indicates how efficiently insulin is processed during metabolism in response to increased externally administered glucose. HbA1c reflects the average blood sugar level until immediately before the test and not at the time of sample collection, because hemoglobin increases with time and according to glucose concentration (Nathan et al., 2007; Nathan et al., 2008). Therefore, it is necessary to investigate the causal effects of these three T2D-related traits in the blood and how they differ in subsequent pathological disorders.

To efficiently identify causal associations between T2D-related traits and various phenotypes without potential biases or confounding and/or reverse causations, Mendelian randomization (MR) can be used to assess how genetic variants act as instruments for instrumental variable (IV) analysis aimed at estimating the causal effect of one trait on another. Using genetic variants as instruments, which are not associated with conventional confounders of observational studies, allows the MR approach to be considered analogous to randomized controlled trials (Burgess and Thompson, 2015). MR analysis requires three assumptions: 1) IVs are strongly associated with intermediate exposure, 2) IVs are independent of confounders, and 3) IVs affect outcomes only through the exposure path. If these assumptions hold, an inverse-variance-weighted (IVW) method provides the most efficient and unbiased estimates of causal effects (Burgess et al., 2020). Various MR methods have been proposed for providing a more robust approach under weaker assumptions (Burgess et al., 2013; Bowden et al., 2015; Bowden et al., 2016a; Bowden et al., 2016b; Verbanck et al., 2018).

The aim of this study was to assess the causal effect of T2D-related traits (FPG, 2h-PG, and HbA1c) on cancers and vascular diseases via MR analysis using several methods, including those measuring sensitivity in the MR-Base platform database (Hemani et al., 2016).

2 Materials and Methods

2.1 Exposure datasets

The exposure traits of interest were FPG, 2h-PG, and HbA1c. The summary statistics for T2D-related traits were obtained through large-scale genome-wide association study (GWAS) meta-analyses of

133,010 non-diabetic individuals from collaborating studies within the Meta-Analysis of Glucose and Insulin related traits Consortium (MAGIC) (Scott et al., 2012). In most of these studies, participants were of European ancestry and adults. A total of ~2.5 million genome-wide directly genotyped or imputed autosomal single-nucleotide polymorphisms (SNPs) were reported, including 36, 9, and 11 SNPs with genome-wide significant ($P < 5 \times 10^{-8}$) associations with FPG, 2h-PG, and HbA1c, explaining 4.8%, 1.7%, and 2.4% of the variance in the trait, respectively. Among these, SNPs were selected as IV candidates not in linkage disequilibrium (LD; $r^2 < 0.001$) or within 10,000 kb of an established signal. To specify final IV sets, available genetic instruments for assessing outcome traits of interest were explored via the MR-Base platform database (<https://www.mrbase.org/>) or through the R package ‘TwoSampleMR’ (<https://rdrr.io/github/MRCIEU/TwoSampleMR/>). To reflect the same reference strand between exposure and outcome, alleles and effects were harmonized using effect/non-effect alleles and minor allele frequency for palindromic SNPs.

2.2 Outcome datasets

Human phenotypes were divided into two categories of diseases or traits known to be related to T2D. The first category was cancer at major sites: breast, gall bladder, lung [adenocarcinoma and squamous cell (SC) carcinoma], ovarian, pancreatic, and thyroid (differentiated types). The second category was vascular disease: coronary kidney disease (CKD), coronary artery disease (CAD), stroke, cardio-embolic stroke, small-vessel stroke, and high-density lipoprotein (HDL)/low-density lipoprotein (LDL) cholesterol levels. We obtained summary SNP-outcome associations with a total of 14 human health phenotypes through the MR-BASE platform. Additionally, information regarding each outcome trait of interest was extracted (e.g., author/study/consortium name, number of cases and controls, publication year, PubMed ID, study population, unit, etc.) and listed in Table 1.

2.3 MR assumptions

The assumptions of MR studies can be represented using causal directed acyclic graphs (DAG) (Figure 1). In a DAG, the genetic variant G_j ($j=1, 2, \dots, J$) and the exposure, X , are denoted as γ_j , and the association between the genetic variant, G_j , and the outcome, Y , is denoted as α_j . Associations between a confounding factor (U) and G_j , X , and Y are denoted as ψ_j , K_x , and K_y , respectively. In a two-sample MR setting, we refer to $\hat{\gamma}_j$ as an estimate from the j^{th} SNP-exposure association (with variance $\sigma_{X_j}^2$) from sample 1 and $\hat{\alpha}_j$ as an estimate from the j^{th} SNP-outcome association (with variance $\sigma_{Y_j}^2$) from sample 2.

$$\text{Sample 1: } \hat{\gamma}_j = \gamma_j + k_x \varphi_j + \epsilon_{X_j}, \text{ var}(\epsilon_{X_j}) = \sigma_{X_j}^2$$

$$\text{Sample 2: } \hat{\alpha}_j = \alpha_j + k_y \varphi_j + \beta(\gamma_j + k_x \varphi_j) + \epsilon_{Y_j}, \text{ var}(\epsilon_{Y_j}) = \sigma_{Y_j}^2$$

The genetic variant, G_j , for valid IVs must satisfy the following three core assumptions; (i) IV1: $\gamma_j \neq 0$, (ii) IV2: $\varphi_j = 0$, (iii) IV3: $\alpha_j = 0$. Furthermore, MR requires a “NO Measurement Error” (NOME) assumption and an Instrument Strength Independent of Direct Effect (InSIDE) assumption. It is important to assess the instrument strength to prevent weak instrument bias on MR analysis. We evaluated weak instruments with mean F-statistics, and the degree of violation of the NOME

assumption was quantified using the previously reported I^2 statistic (ranging 0–1) (Bowden et al., 2016b). Higher values for I^2 indicate lesser dilution of the causal effect estimate.

2.4 MR methods

Using all genetic variants, G_j , that satisfy the three IV assumptions and the NOME and InSIDE assumptions, the causal effect of exposure on the outcome can be consistently estimated from the ratio estimates and averaged using an IVW method (Burgess et al., 2013). The IVW estimate is the most efficient method when all genetic variants satisfy all three IV assumptions. Cochran's Q statistic was used to quantify heterogeneity (Greco et al., 2015; Bowden et al., 2017).

However, the estimate could be biased if one or more variants are invalid. The weighted median method provides valid causal estimates, even if up to 50% of the instruments are invalid. The median is unaffected by outliers, making the weighted median estimate insensitive to a pleiotropic genetic variant. Causal effects are obtained from the weighted median of the ratio estimates in genetic instruments, resulting in smaller standard errors receiving more weight (Bowden et al., 2016a).

The MR-Egger method allows all SNPs to be used as invalid instruments but requires variants to satisfy the InSIDE assumption, enabling estimation of appropriate causal effects in the presence of pleiotropic effects (Bowden et al., 2015). This model is suitable for linear regression and the intercept term, β_{0E} , is interpreted as the average horizontal pleiotropic effect across the genetic variants (Bowden et al., 2015). Rücker's Q' statistic from MR-Egger was used to quantify directional heterogeneity (Greco et al., 2015; Bowden et al., 2017). If estimates of β_{0E} equal zero, the MR-Egger slope estimate will be the same as the IVW estimate (Burgess and Thompson, 2015). However, when the I^2 statistic quantifying the strength of NOME violation for IVs for the MR-Egger method is low, a magnitude of regression dilution still occurs. In cases where the NOME assumption is violated, the SIMEX method can be used to correct attenuation bias (Bowden et al., 2016b).

Violation of IV3 (no horizontal pleiotropy) can raise a severe bias in MR analysis. The MR-PRESSO test has an advantage over MR-Egger, in that it identifies and removes pleiotropic SNPs. The test comprises three parts: 1) the MR-PRESSO global test detects horizontal pleiotropy, 2) the outlier-corrected causal estimate corrects for the detected horizontal pleiotropy, and 3) the MR-PRESSO distortion test estimates whether the causal estimates differ significantly ($P < 0.05$) following adjustment for the outliers (Verbanck et al., 2018). Therefore, MR-PRESSO results are preferable in the presence of a horizontal pleiotropic effect.

The appropriate methods differ according to the assumptions satisfied, and the most suitable choices are presented in Table 2 and 3. The IVW method is the most efficient way to estimate the causal effect when all genetic variants are valid instruments (Burgess et al., 2020). In cases where the MR assumption of no pleiotropy is not met, the MR-PRESSO test detects possible outliers and provides consistent estimates following outlier removal (Burgess and Thompson, 2017). When some genetic variants are invalid (<50%), the weighted median approach can be used as an alternative method of providing a consistent estimate (Bowden et al., 2016a). By contrast, MR-Egger can obtain a causal estimate by correcting directional pleiotropy but has the disadvantage of low power (Bowden et al., 2015). If the NOME assumption is violated ($I^2 < 90\%$), the MR-Egger (SIMEX) method would be suitable (Bowden et al., 2016b).

2.5 Bidirectional MR analysis

We conducted bidirectional MR analysis to investigate the presence of reverse causality among associations between T2D-related traits and outcomes of interest. This was performed by switching the exposure and outcomes in opposite directions.

2.6 MR power analysis

Power calculations were conducted at <https://sb452.shinyapps.io/power/> (Burgess et al., 2020). The proportion of variance in the exposure explained by the genetic variants (R^2) were required for MR power analysis, with 0.048 (FPG), 0.017 (2h-PG), and 0.024 (HbA1c) used, respectively. We assumed odds ratios (ORs) of 1.1 and 1.2 for binary outcomes and changes in outcomes in standard deviation (SD) units per SD change in exposure (0.1 and 0.2) for continuous outcomes. Statistical power evaluations at the conservative significance level [0.007 (Bonferroni correction with 7 tests)] are plotted in Figure 2.

3 Results

A total of 34, 7, and 11 genetic variants associated with FPG, 2h-PG, and HbA1c respectively, were available as potential instruments from studies included in MAGIC. Each IV set showed genome-wide significant ($P < 5 \times 10^{-8}$) associations with T2D-related traits and were not in LD or within 10,000 kb of an established signal. To investigate IV quality, we generated F-statistics, I^2 values, and P -values for Cochran's Q statistic from IVW, Rucker's Q' statistic from MR-Egger, and MR-PRESSO global test (Table 4). All instruments used for MR analyses had F-statistics >10 , indicating no evidence of weak instrument bias. Rejection of the null hypothesis of the Cochran's Q statistic for heterogeneity suggested potential pleiotropy in the genetic variants and did not indicate that the InSIDE assumptions were invalid. When the pleiotropic effect was present, MR-Egger (with and without SIMEX), and MR-PRESSO) were performed rather than using the IVW method. The instruments corresponding to FPG satisfied the NOME assumption ($I^2 > 90$) but only partially satisfied this for HbA1c ($I^2 > 90$ in only some cases) and did not satisfy this in the case of 2h-PG ($I^2 < 90$). When the NOME assumption was violated, the results of MR-Egger (SIMEX) were generated. Using these IVs, we performed MR analyses for a total of 14 human health phenotypes, with all results (3 exposures $\times$ 13 phenotypes $\times$ 5 methods = 185 results) presented in Supplementary Table 1. Application of Bonferroni correction to each disease category (0.05/6 = 0.008 for cancer; and 0.05/7 = 0.007 for vascular disease) revealed two significant phenotypes (CAD and LDL level) associated with T2D-related traits (Table 5). Additionally, we confirmed these relationships through bidirectional and replication analyses (Tables 5 and 6).

3.1 T2D-related traits and cancers

We considered FPG, 2h-PG, and HbA1c as exposure traits. For FPG, IVs for lung, ovarian, pancreatic, and thyroid cancer satisfied the IV assumptions (F statistics >10 , $I^2 > 90$, Q - $P > 0.05$), and IVW was selected for MR analyses (Table 3). No significant causal association was observed between FPG and lung ($P=0.721$), ovarian ($P=0.632$), pancreatic ($P=0.768$), and thyroid ($P=0.612$) cancer. A pleiotropic effect was observed in breast cancer through Q ($P < 0.001$), Q' ($P < 0.001$) statistics, and the MR-PRESSO global test ($P < 0.001$), and MR-PRESSO did not yield significant outcomes ($P=0.364$). The NOME assumption was violated in SC lung cancer ($I^2 < 90$), and the MR-Egger (SIMEX) method was used. The MR-Egger (SIMEX) method yielded nominally significant ($P < 0.05$) causal effects ($P=0.032$). Furthermore, when 2h-PG was considered an exposure trait, IVs for all cancers, except for breast cancer, we found no weak instrument bias ($F > 10$) and no

heterogeneity (Q - $P > 0.05$, Q' - $P > 0.05$, MR-PRESSO global test- $P > 0.05$), and the IVW method was used. However, IVs for breast cancer have a measurement error ($I^2 < 90$), and the MR-Egger (SIMEX) method was used. None of the IVs were significant for breast ($P = 0.303$), lung ($P = 0.721$), SC lung ($P = 0.037$), ovarian ($P = 0.632$), pancreatic ($P = 0.768$), and thyroid ($P = 0.612$) cancer. Moreover, regarding HbA1c, evidence of violations of IV assumptions for all cancers was obtained (F statistics > 10 , Q - $P > 0.05$, Q' - $P > 0.05$, MR-PRESSO global test- $P > 0.05$), and IVW was applied. No significant association was observed between HbA1c and breast ($P = 0.922$), lung ($P = 0.173$), SC lung ($P = 0.115$), ovarian ($P = 0.719$), pancreatic ($P = 0.374$), and thyroid ($P = 0.417$) cancer.

For lung, breast, and ovarian cancer, we assumed an OR of 1.2 and we determined the statistical power at between 40% and 70%. The highest power was observed for FPG with the highest R^2 , followed by HbA1c and 2h-PG. The estimated statistical power was the highest ($> 80\%$) for SC lung cancer for all T2D-related traits owing to a sample size of $> 100,000$ individuals if the standardized effect size is assumed to be same. However, for pancreatic and thyroid cancers, the sample size was small (3,835 and 1,080, respectively), thus decreasing the statistical power, indicating the possibility of false-negative results. The overall estimated power (Figure 2) revealed no causal effect of FPG, 2h-PG, and HbA1c on breast, lung, SC lung, ovarian, pancreatic, and thyroid cancers ($P < 0.008$ after Bonferroni correction) (Supplementary Table 1).

3.2 T2D-related traits and vascular diseases

All data for vascular diseases were from a sample size of $> 100,000$ patients, giving them a power of $\geq 80\%$, except for detecting an OR of 1.1. We found no causal effect of FPG, 2h-PG, or HbA1c on CKD, HDL level, stroke, or stroke subtype, but two significant causal relationships were observed for FPG with CAD and HbA1c with HDL level. Interestingly, three T2D-related traits used as criteria for diagnosing T2D showed different results for the same phenotype. First, on using FPG as an exposure trait, IVs for CKD and cardio-embolic stroke strongly satisfied the IV assumptions (F statistics > 10 , $I^2 > 90$, F statistics > 10 , Q - $P > 0.05$, Q' - $P > 0.05$, MR-PRESSO global test- $P > 0.05$), and the IVW approach was selected (Table 2). However, FPG had no causal effects on CKD ($P = 0.351$) and cardio-embolic stroke ($P = 0.118$) were observed, but was nominally significant on small-vessel stroke ($P = 0.025$). In the case of CAD, HDL/LDL cholesterol, and stroke, we found heterogeneity (Q - $P < 0.05$, Q' - $P < 0.05$, MR-PRESSO global test- $P < 0.05$), and the MR-PRESSO method was applied. Nominally significant results were observed for CAD (MR-PRESSO $P = 0.045$) and non-significant results were observed for HDL cholesterol ($P = 0.265$), LDL cholesterol ($P = 0.225$), and stroke ($P = 0.135$). Second, when 2h-PG was used as an exposure trait, IVs for CKD, stroke, cardio-embolic stroke, and small-vessel stroke strongly satisfied the IV assumptions (F statistics > 10 , F statistics > 10 , Q - $P > 0.05$, Q' - $P > 0.05$, MR-PRESSO global test- $P > 0.05$), and the IVW method used. Non-significant causal effects were observed for 2h-PG on CKD ($P = 0.183$), stroke ($P = 0.338$), cardio-embolic stroke ($P = 0.530$), and small-vessel stroke ($P = 0.084$). In the case of CAD, HDL/LDL cholesterol, all have measurement error ($I^2 < 90$) with heterogeneity (Q - $P < 0.05$, Q' - $P < 0.05$, MR-PRESSO global test- $P < 0.05$), and the MR-Egger (SIMEX) method was used. Non-significant causal effects were observed for 2h-PG on CAD ($P = 0.301$), HDL cholesterol ($P = 0.074$), and LDL cholesterol ($P = 0.241$). Third, when HbA1c was considered an exposure trait, IVs for CKD, HDL cholesterol, stroke, cardio-embolic stroke and small-vessel stroke strongly satisfied the IV assumptions (F statistics > 10 , Q - $P > 0.05$, Q' - $P > 0.05$, MR-PRESSO global test- $P > 0.05$), and the IVW method was selected. However, no causal effects of HbA1c were observed on CKD ($P = 0.337$), HDL cholesterol ($P = 0.206$), and stroke ($P = 0.567$), but there were nominally significant implications for cardio-embolic stroke ($P = 0.023$) and small-vessel stroke ($P = 0.046$). Owing to the heterogeneity in CAD and LDL cholesterol (Q - $P < 0.05$, Q' - $P < 0.05$, MR-PRESSO global test- $P < 0.05$), the MR-

245 PRESSO method was considered, and nominally significant results were obtained for LDL
246 cholesterol ($P=0.010$), but non-significant for CAD ($P=0.069$).

247 Significant effects were found for FPG-CAD and HbA1c-LDL cholesterol. Regarding FPG-CAD, all
248 SNP-exposure and SNP-outcome effects are presented in Supplementary Table 2. We found two
249 SNPs significantly correlated with CAD (rs1260326: $P = 2.40 \times 10^{-5}$; and rs7651090: $P = 1.20 \times$
250 10^{-5}); however, given that they exhibited balanced pleiotropy, they were not excluded from the
251 analysis (but were excluded from MR-PRESSO tests). A generated funnel plot showed symmetry,
252 indicating heterogeneity due to horizontal pleiotropy (Figure 3A). The associations of the variants
253 with FPG and CAD are shown in a scatter plot with five MR-fitted lines (Figure 3B). Thirty-four
254 SNPs were considered instruments, and no weak instrument bias was noted with no violation of
255 NOME assumption, albeit with heterogeneity. Therefore, we assessed the other several sensitivity
256 methods, and observed causal effects of CAD on FPG from the weighted median ($P<0.001$).
257 Moreover, we verified that reverse causality did not exist (Table 6). In the replication study using the
258 same IVs and different GWAS data for outcome (PmID = 29212778, N = 296,525, P = European,
259 and unit = logOR), there was no weak instrument bias of IVs (N=34, F statistics 43.5) but the
260 heterogeneity assumption was violated ($Q-P<0.05$, $Q'-P<0.05$, MR-PRESSO global test- $P<0.05$).
261 Therefore, MR-PRESSO was selected, and we found that FPG has a positively causal effect on CAD
262 in accordance with the MR-PRESSO method ($P = 0.002$) (Table 5). On bidirectional MR analysis in
263 the replication study, 83 SNPs were considered instrument variables. Weak instrument bias (F-
264 statistics 77.2) and the NOME assumption ($I^2 = 92.4$) were preserved; however, heterogeneity was
265 observed $Q-P<0.05$, $Q'-P<0.05$, MR-PRESSO global test- $P<0.05$). MR-PRESSO revealed no causal
266 effect of CAD on FPG (Table 6).

267 Regarding HbA1c and LDL cholesterol, SNP-exposure and SNP-outcome effects (Supplementary
268 Table 3) indicated that one SNP was significantly correlated with LDL level (rs1800562; $P=4.42 \times$
269 10^{-4}), with this SNP excluded from MR-PRESSO analysis. Figure 4A shows a funnel plot indicating
270 slight non-symmetry, suggesting the presence of heterogeneity due to horizontal pleiotropy. The
271 scatter plot in Figure 4B shows the associations of the variants with HbA1c and LDL level. Eleven
272 SNPs were considered instruments, and no weak instrument bias was noted with no violation of
273 NOME assumption, albeit with heterogeneity. Therefore, we assessed several other sensitivity
274 methods, and observed causal effects of HbA1c on LDL cholesterol from MR-Egger (SIMEX)
275 ($P=0.007$). In addition, reverse causality was not identified (Table 6). Seventy-four SNPs were
276 considered instruments, and no weak instrument bias was noted (F-statistics 153.9), with no violation
277 of the NOME assumption ($I^2 = 97.7$). However, heterogeneity was observed ($Q-P<0.05$, $Q'-P<0.05$,
278 MR-PRESSO global test- $P<0.05$), and MR-PRESSO revealed no causal effect of LDL cholesterol on
279 HbA1c ($P=0.234$). Replication analysis using the same IVs and different GWAS data for the
280 outcome-SNP effect (pmID = 28887542, N = 9,961, P = European, unit = mg/dL) revealed no
281 evidence of a weak instrument bias (N=11, F-statistics 77.6) and no heterogeneity ($Q-P>0.05$, $Q'-$
282 $P>0.05$, MR-PRESSO global test- $P>0.05$), but the NOME assumption ($I^2 = 87.9$) was violated.
283 Therefore, MR-PRESSO revealed significant results for the causal effect of HbA1c on LDL
284 cholesterol ($P=0.032$) (Table 5). On bidirectional MR analysis for the replication study, 4 SNPs were
285 considered instrument variables. No weak instrument bias (F-statistics 42.9) and no heterogeneity ($Q-$
286 $P>0.05$, $Q'-P>0.05$, MR-PRESSO global test- $P>0.05$) were observed; however, a violation of the
287 NOME assumption ($I^2 = 4$) was noted. Accordingly, IVW was considered, and no causal effect of
288 LDL cholesterol on HbA1c was observed ($P=0.681$) (Table 6).

289 4 Discussion

In this study, we performed MR analysis of the effect of T2D-related traits on 13 human health phenotypes using GWAS results and data from the MR-BASE registry. In particular, MR analysis was conducted according to three T2D-related criteria (FPG and 2h-PG from the OGTT and HbA1c). MR analyses reduce potential confounding effects and reverse causation, and our results are concurrent with those of previous epidemiological studies. Previous large meta-analyses or systematic reviews of epidemiological studies show that the association between T2D and cancer development is unclear (Tsilidis et al., 2015). Moreover, most epidemiological studies report limitations in findings of T2D-related association with cancers, because they were based on self-reported health assessments with high specificity (>90%) but low sensitivity (66%) as compared with medical records (Okura et al., 2004). Recently, results of MR analysis indicated no strong evidence supporting a causal relationship between T2D and major solid tumors (stomach, colorectal, liver, pancreas, lung, breast, and prostate) (Goto et al., 2020). Similarly, in the present study, analysis of European data from the MR-Base registry revealed no significant causal effect of T2D-related traits on breast, lung, SC lung, ovarian, pancreatic, and thyroid cancers. Although T2D and cancer share a number of risk factors, such as hyperglycemia, insulin resistance, and dyslipidemia, a relationship between the diseases has not been fully demonstrated (Vigneri et al., 2009). Additionally, studies have reported correlations between hypoglycemic agents and cancer incidence, although these findings remain controversial (Alimova et al., 2009; Currie et al., 2009).

In T2D patients, the risk of death from cardiovascular disease increases along with elevated FPG and HbA1c levels, with HbA1c level correlated with microvascular and macrovascular complications (Kannel and McGee, 1979; Group, 1998; Okura et al., 2004). Therefore, hyperglycemia represents a strong independent factor for cardiovascular disease, with the risk increasing 2- to 3-fold in men and 3- to 4-fold in women diagnosed with T2D relative to those without T2D (Kannel and McGee, 1979; Okura et al., 2004). A longitudinal study involving follow-up for 8 years of 2,363 non-diabetic adults between the ages of 50 and 75 years reported significant association between 2h-PG and HbA1c levels and an increased risk of death from cardiovascular disease (De Vegt et al., 1999). Moreover, that study identified HbA1c level as not only predictive of improved better mortality from cardiovascular disease relative to FPG and 2h-PG (Park et al., 1996) but also an independent risk factor for atherosclerosis and cardiovascular disease independent of T2D (Nakamura et al., 1993; Kanauchi et al., 2001). In the present study, our findings indicated that vascular disease and LDL level were significantly linked with HbA1c level but not FPG or 2h-PG.

We found that different characteristics related to FPG, 2h-PG, and HbA1c differentially influenced IV characteristics. The 2h-PG results from an OGTT represent a standard test for T2D diagnosis. Although 2h-PG testing is more highly sensitive and specific than FPG testing, its low reproducibility is a disadvantage (Peters et al., 1996). The low reproducibility is a consequence of changes in 2-h glucose concentrations for each measurement within a 48-h or 1-week time period in the same individual. On the other hand, FPG testing is simple and reproducible; however, the sensitivity for T2D diagnosis is poor, because it does not allow accurate identification of hyperglycemia after glucose load (Davidson et al., 1999). HbA1c reflects overall tissue protein glycation and can better reflect the overall biological effect of blood sugar as a 3-month average blood sugar estimate (Peterson et al., 1998); however, HbA1c measurements can be affected by hemoglobin disease, chronic renal failure, testing methods, and/or specific dosage (Barr et al., 2002). Therefore, these findings suggest that the measurement error associated with SNP-exposure associations might be large when using any of these criteria. A previous study showed that calculation of the I^2 value confirmed the inadequacy of the NOME assumption due to measurement error related to 2h-PG testing (Bowden et al., 2016b). Furthermore, reports indicated that the HbA1c level shows less variability in day-to-day within-person variance than FPG (<2% for HbA1c vs. 12–

15% for FPG) (Ollerton et al., 1999), and the intra-individual coefficient of variation for FPG (6.4%) is less than that for 2h-PG (16.7%) (Mooy et al., 1996). Therefore, MR analysis using 2h-PG as an exposure can be expected to increase the reliability of MR-Egger (SIMEX) findings relative to other methods. In the cases of FPG and HbA1c, IVW results and the sensitivity analysis methods should be examined more broadly.

We performed MR analysis using public data from previous large-scale GWAS studies. Producing in-house genetic data is expensive and requires substantial human resources, making it difficult for many individual researchers lacking access to appropriate datasets. A two-sample MR approach represents an effective method for discovering novel causal relationships through the use of available large-scale GWAS datasets. Additionally, MR analysis excludes confounding effects by using SNPs associated with exposure as genetic instruments, which also reduces the adverse effects of inaccurate data on hindering identification of relationships between exposure and outcome.

The present MR analysis has several limitations. First, some subjects may have overlapped between the two data sets with respect to the estimates of instrument-exposure and instrument-outcome, which could lead to inflated type 1 error rates and false-positive findings (Burgess et al., 2016). Furthermore, MR analyses are based on the GWAS. GWAS requires numerous subjects, often in multiple cohorts. Disease definition can differ among different cohorts. Third, we mostly included studies involving a predominantly European population with few individuals of other ancestries (mixed); hence, the present results may not be applicable to other racial backgrounds. Nevertheless, the present results support the results of previous epidemiology studies and promote further studies in this field.

5 Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

6 Author Contributions

J.J. analyzed and interpreted the results and wrote the manuscript. S.W. and S.L. designed the study. All authors revised this paper critically for important intellectual content.

7 Funding

This study was supported by the National Research Foundation of Korea (2017M3A9F3046543).

8 Acknowledgements

None

9 Data Availability Statement

All datasets presented in this study are included in the supplementary material and available at

<https://www.mrbase.org/> and <https://gwas.mrcieu.ac.uk/>.

10 References

- Alimova, I.N., Liu, B., Fan, Z., Edgerton, S.M., Dillon, T., Lind, S.E., and Thor, A.D. (2009). Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. *Cell Cycle* 8, 909-915.
- Association, A.D. (2010). Standards of medical care in diabetes—2010. *Diabetes Care* 33, S11-S61.
- Barr, R.G., Nathan, D.M., Meigs, J.B., and Singer, D.E. (2002). Tests of glycemia for the diagnosis of type 2 diabetes mellitus. *Ann. Int. Med.* 137, 263-272.
- Bax, J.J., Young, L.H., Frye, R.L., Bonow, R.O., Steinberg, H.O., and Barrett, E.J. (2007). Screening for coronary artery disease in patients with diabetes. *Diabetes Care* 30, 2729-2736.
- Bowden, J., Davey Smith, G., and Burgess, S. (2015). Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int. J. Epidemiol.* 44, 512-525.
- Bowden, J., Davey Smith, G., Haycock, P.C., and Burgess, S. (2016a). Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. *Genet. Epidemiol.* 40, 304-314.
- Bowden, J., Del Greco M, F., Minelli, C., Davey Smith, G., Sheehan, N.A., and Thompson, J.R. (2016b). Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I² statistic. *Int. J. Epidemiol.* 45, 1961-1974.
- Bowden, J., Del Greco M, F., Minelli, C., Davey Smith, G., Sheehan, N., & Thompson, J. (2017). A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. *Stat. Med.* 36(11), 1783-1802.
- Burgess, S., Butterworth, A., and Thompson, S.G. (2013). Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet. Epidemiol.* 37, 658-665.
- Burgess, S., Davies, N.M., and Thompson, S.G. (2016). Bias due to participant overlap in two-sample Mendelian randomization. *Genet. Epidemiol.* 40, 597-608.
- Burgess, S., Smith, G.D., Davies, N.M., Dudbridge, F., Gill, D., Glymour, M.M., Hartwig, F.P., Holmes, M.V., Minelli, C., and Relton, C.L. (2020). Guidelines for performing Mendelian randomization investigations. *Wellcome Open Research* 4, 186.
- Burgess, S., and Thompson, S.G. (2015). *Mendelian randomization: methods for using genetic variants in causal estimation*. CRC Press.
- Burgess, S., and Thompson, S.G. (2017). Interpreting findings from Mendelian randomization using the MR-Egger method. *Eur. J. Epidemiol.* 32, 377-389.
- Collaboration, E.R.F. (2011). Diabetes mellitus, fasting glucose, and risk of cause-specific death. *N. Engl. J. Med.* 364, 829-841.
- Currie, C., Poole, C., and Gale, E. (2009). The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. *Diabetologia* 52, 1766-1777.
- Davidson, M.B., Schriger, D.L., Peters, A.L., and Lorber, B. (1999). Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. *JAMA* 281, 1203-1210.

- 412 De Vegt, F., Dekker, J., Ruhe, H., Stehouwer, C., Nijpels, G., Bouter, L., and Heine, R. (1999).
413 Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn
414 population: the Hoorn Study. *Diabetologia* 42, 926-931.
- 415 Gavin Iii, J.R., Alberti, K., Davidson, M.B., and DeFronzo, R.A. (1997). Report of the expert
416 committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 20, 1183.
- 417 Gleissner, C.A., Galkina, E., Nadler, J.L., and Ley, K. (2007). Mechanisms by which diabetes
418 increases cardiovascular disease. *Drug Discov. Today: Dis. Mech.* 4, 131-140.
- 419 Goto, A., Yamaji, T., Sawada, N., Momozawa, Y., Kamatani, Y., Kubo, M., Shimazu, T., Inoue, M.,
420 Noda, M., and Tsugane, S. (2020). Diabetes and cancer risk: A Mendelian randomization
421 study. *nt. J. Cancer* 146, 712-719.
- 422 Greco M, F. D., Minelli, C., Sheehan, N. A., & Thompson, J. R. (2015). Detecting pleiotropy in
423 Mendelian randomisation studies with summary data and a continuous outcome. *Stat. Med.*
424 34(21), 2926-2940.
- 425 Group, U.P.D.S. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared
426 with conventional treatment and risk of complications in patients with type 2 diabetes
427 (UKPDS 33). *The Lancet* 352, 837-853.
- 428 Hemani, G., Zheng, J., Wade, K.H., Laurin, C., Elsworth, B., Burgess, S., Bowden, J., Langdon, R.,
429 Tan, V., and Yarmolinsky, J. (2016). MR-Base: a platform for systematic causal inference
430 across the phenome using billions of genetic associations. *BioRxiv*, 078972.
- 431 Johnson, J., Carstensen, B., Witte, D., Bowker, S., Lipscombe, L., Renahan, A., Diabetes, and
432 Consortium, C.R. (2012). Diabetes and cancer (1): evaluating the temporal relationship
433 between type 2 diabetes and cancer incidence. *Diabetologia* 55, 1607-1618.
- 434 Kanauchi, M., Tsujimoto, N., and Hashimoto, T. (2001). Advanced glycation end products in
435 nondiabetic patients with coronary artery disease. *Diabetes Care* 24, 1620-1623.
- 436 Kannel, W.B., and Mcgee, D.L. (1979). Diabetes and cardiovascular disease: the Framingham study.
437 *JAMA* 241, 2035-2038.
- 438 Laakso, M. (1999). Hyperglycemia and cardiovascular disease in type 2 diabetes. *Diabetes* 48, 937-
439 942.
- 440 Mooy, J., Grootenhuys, P., De Vries, H., Kostense, P., Popp-Snijders, C., Bouter, L., and Heine, R.
441 (1996). Intra-individual variation of glucose, specific insulin and proinsulin concentrations
442 measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn
443 Study. *Diabetologia* 39, 298-305.
- 444 Nakamura, Y., Horii, Y., Nishino, T., Shiiki, H., Sakaguchi, Y., Kagoshima, T., Dohi, K., Makita, Z.,
445 Vlassara, H., and Bucala, R. (1993). Immunohistochemical localization of advanced
446 glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. *Am.*
447 *J. Pathol.* 143, 1649.
- 448 Nathan, D., Turgeon, H., and Regan, S. (2007). Relationship between glycated haemoglobin levels
449 and mean glucose levels over time. *Diabetologia* 50, 2239-2244.
- 450 Nathan, D.M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D., and Heine, R.J. (2008). Translating
451 the A1C assay into estimated average glucose values. *Diabetes Care* 31, 1473-1478.
- 452 Nesto, R. (2001). CHD: a major burden in type 2 diabetes. *Acta Diabetol.* 38, S3-S8.

453 Okura, Y., Urban, L.H., Mahoney, D.W., Jacobsen, S.J., and Rodeheffer, R.J. (2004). Agreement
454 between self-report questionnaires and medical record data was substantial for diabetes,
455 hypertension, myocardial infarction and stroke but not for heart failure. *J. Clin. Epidemiol.*
456 57, 1096-1103.

457 Ollerton, R.L., Playle, R., Ahmed, K., Dunstan, F.D., Luzio, S.D., and Owens, D.R. (1999). Day-to-
458 day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects.
459 *Diabetes Care* 22, 394-398.

460 Park, S., Barrett-Connor, E., Wingard, D.L., Shan, J., and Edelstein, S. (1996). GHb is a better
461 predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women
462 without diabetes: the Rancho Bernardo Study. *Diabetes Care* 19, 450-456.

463 Peters, A.L., Davidson, M.B., Schriger, D.L., and Hasselblad, V. (1996). A clinical approach for the
464 diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. *JAMA* 276,
465 1246-1252.

466 Peterson, K.P., Pavlovich, J.G., Goldstein, D., Little, R., England, J., and Peterson, C.M. (1998).
467 What is hemoglobin A1c? An analysis of glycated hemoglobins by electrospray ionization
468 mass spectrometry. *Clin. Chem.* 44, 1951-1958.

469 Scott, R.A., Lagou, V., Welch, R.P., Wheeler, E., Montasser, M.E., Mägi, R., Strawbridge, R.J.,
470 Rehnberg, E., Gustafsson, S., and Kanoni, S. (2012). Large-scale association analyses identify
471 new loci influencing glycemic traits and provide insight into the underlying biological
472 pathways. *Nat. Genet.* 44, 991.

473 Tsilidis, K.K., Kasimis, J.C., Lopez, D.S., Ntzani, E.E., and Ioannidis, J.P. (2015). Type 2 diabetes
474 and cancer: umbrella review of meta-analyses of observational studies. *BMJ.* 350, g7607.

475 Verbanck, M., Chen, C.-Y., Neale, B., and Do, R. (2018). Detection of widespread horizontal
476 pleiotropy in causal relationships inferred from Mendelian randomization between complex
477 traits and diseases. *Nat. Genet.* 50, 693-698.

478 Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., and Vigneri, R. (2009). Diabetes and cancer.
479 *Endocr.-Relat. Cancer* 16, 1103-1123.

480 Young, L.H., Frans, J.T., Chyun, D.A., Davey, J.A., Barrett, E.J., Taillefer, R., Heller, G.V.,
481 Iskandrian, A.E., Wittlin, S.D., and Filipchuk, N. (2009). Cardiac outcomes after screening
482 for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a
483 randomized controlled trial. *JAMA* 301, 1547-1555.

491 **Table 1.** Description of data from MR-Base based on the phenotype

Category	Trait	Consortium/ First author	PubMed ID	Unit	No. of cases	No. of controls	No. of SNPs	Population
1. Cancer	Breast cancer	BCAC	25751625	LogOR	15,748	18,084	13,011,123	European
	Lung cancer	ILCCO	24880342	LogOR	11,348	15,861	8,945,893	European
	Lung cancer (SC)	ILCCO	24880342	LogOR	3,275	150,038	8,893,750	European
	Ovarian cancer	OCAC	28346442	LogOR	1,366	40,941	11,403,952	European
	Pancreatic cancer	PanScan1	19648918	LogOR	1,896	1,939	521,863	European
	Thyroid cancer	Kohler A	23894154	LogOR	649	431	572,028	European
2. Vascular disease	CAD	VanderHarst P	29212778	LogOR	122,733	424,528	7,934,254	European
	CKD	CKDGen	26831199	LogOR	12,385	104,780	2,191,877	Mixed
	HDL cholesterol	GLGC	24097068	SD	—	187,167	2,447,442	Mixed
	LDL cholesterol	GLGC	24097068	SD	—	173,082	2,437,752	Mixed
	Stroke	Malik R	29531354	LogOR	40,585	406,111	7,633,440	European
	(Cardio-embolic)	Malik R	29531354	LogOR	7,193	406,111	8,271,294	European
	(Small-vessel)	Malik R	29531354	LogOR	5,386	192,662	6,150,261	European

492 SC, squamous cell; SD, standard deviation; CKD, chronic kidney disease; CAD, coronary artery disease; LDL, low-density lipoprotein; HDL, high-
493 density lipoprotein; logOR, log odds ratio.

Table 2. Recommended MR methods by assumption of IVs

No weak IVs (F>10)	NOME	No Heterogeneity	Recommended Methods
Satisfied	Satisfied	Satisfied	IVW
Satisfied	Satisfied	At least one violated	→ Table 2
Satisfied	Violated	Satisfied	IVW
Satisfied	Violated	At least one violated	MR-Egger (SIMEX)
Violated	Satisfied	Satisfied	Weighted median
Violated	Satisfied	At least one violated	→ Table 2
Violated	Violated	Satisfied	MR-Egger (SIMEX)
Violated	Violated	At least one violated	MR-Egger (SIMEX)

IV, instrument variable; NOME, NO Measurement Error; IVW, inverse-variance-weighted; SIMEX, simulation extrapolation;

Table 3. Recommended MR methods by heterogeneity test

Causal effect of type-2 diabetes

Q test [†]	Q' test [†]	MR-PRESSO global test [‡]	Recommended Methods
			IVW
✓	✓		MR-Egger
	✓		IVW
✓			MR-Egger
		✓	IVW, if there is no weak IV MR- MR-PRESSO, otherwise
✓	✓	✓	MR-PRESSO
	✓	✓	IVW, if there is no weak IV (F>10) MR- MR-PRESSO, ow (F<10)
✓		✓	MR-Egger, MR-PRESSO

517 ✓: significant (heterogeneity exists)

518 [†]Greco et al., 2015; Bowden et al., 2017

519 [‡] Verbanck et al., 2018

520 IV, instrument variable; IVW, inverse–variance–weighted; MR-PRESSO, MR-Pleiotropy RESidual Sum and
521 Outlier

522

523

524

Causal effect of type-2 diabetes

	FPG ($R^2 = 0.048$)				2h-PG ($R^2 = 0.017$)				HbA1c ($R^2 = 0.024$)			
	N	F	I^2 (%)	Q Q' RSS	N	F	I^2 (%)	Q Q' RSS	N	F	I^2 (%)	Q Q' RSS
1. Cancer												
Breast cancer	34	130.5	96.8	<0.001 <0.001 <0.001	7	43.5	29.8	<0.001 0.019 0.023	11	77.6	92.2	0.110 0.249 0.371
Lung cancer	33	133.0	97.3	0.182 0.183 0.211	7	43.5	36.2	0.322 0.397 0.258	11	77.6	87.6	0.021 0.063 0.089
SC lung cancer	33	43.5	40.1	0.599 0.553 0.477	7	43.5	40.1	0.875 0.786 0.913	11	77.6	87.9	0.198 0.154 0.216
Ovarian cancer	33	133.5	97.4	0.530 0.490 0.412	7	43.5	28.1	0.323 0.224 0.362	11	77.6	87.8	0.243 0.334 0.298
Pancreatic cancer	25	111.7	96.4	0.138 0.122 0.199	6	45.0	31.8	0.710 0.594 0.642	8	82.1	90.9	0.239 0.186 0.214
Thyroid cancer	27	144.9	97.9	0.183 0.248 0.275	5	47.4	21.9	0.434 0.703 0.621	9	81.7	91.2	0.882 0.899 0.885
2. Cardiovascular disease												
CAD	34	130.5	97.3	<0.001 <0.001 <0.001	7	43.5	23.0	<0.001 <0.001 <0.001	11	77.6	88.0	0.002 0.014 0.018
CKD	32	135.8	97.4	0.106 0.114 0.151	7	43.5	29.1	0.482 0.451 0.395	10	82.1	86.5	0.632 0.548 0.421
HDL cholesterol	34	130.5	97.3	<0.001 <0.001 <0.001	7	43.5	2.4	<0.001 <0.001 <0.001	11	77.6	90.9	0.545 0.589 0.436
LDL cholesterol	34	130.8	97.2	<0.001 <0.001 <0.001	7	43.5	5.7	<0.001 <0.001 <0.001	11	77.6	91.1	<0.001 <0.001 <0.001
Stroke	34	130.5	97.3	<0.001 <0.001 <0.001	7	43.5	39.9	0.069 0.051 0.067	11	77.6	86.0	0.075 0.084 0.092
(Cardio-embolic)	34	130.5	97.4	0.498 0.649 0.557	7	43.4	35.2	0.733 0.611 0.694	11	77.6	88.7	0.255 0.247 0.275
(Small-vessel)	32	135.8	97.6	0.038 0.130 0.199	7	43.5	55.6	0.675 0.636 0.645	10	76.88	86.6	0.556 0.522 0.512

Table 4. Assumption check for instrumental variables

F, F-statistic; Q, P -value for the Q-test from IVW; Q', P -value for the Q'-test from MR-Egger; RSS, P -value for MR-PRESSO global test, SC, squamous cell; CKD, chronic kidney disease; CAD, coronary artery disease; LDL, low-density lipoprotein; HDL, high-density lipoprotein; FPG, fasting plasma glucose; 2h-PG, 2-h plasma glucose; HbA1c, hemoglobin A1c.

Table 5. Significant results from MR and replication analyses

No.	Exposure	Outcome	MR method	Parameter	N	Original study		N	Replication study	
						Estimate (95% CI)	P		Estimate (95% CI)	P
1	FPG	CAD	IVW	Estimate	34	0.21 (0.05, 0.37)	0.012	34	0.14 (−0.02, 0.29)	0.078
			MR Egger	Intercept		0.00 (−0.01, 0.01)	0.530		0.01 (0.00, 0.02)	0.090
				Slope		0.13 (−0.18, 0.43)	0.426		−0.07 (−0.36, 0.22)	0.626
			MR Egger (SIMEX)	Intercept		0.00 (−0.01, 0.01)	0.443		0.00 (−0.01, 0.01)	0.769
				Slope		0.22 (0.06, 0.39)	0.014		0.144 (−0.02, 0.30)	0.087
			MR-PRESSO (O-C)	Estimate	32	0.18 (0.01, 0.35)	0.045	28	0.19 (0.07, 0.32)	0.002
			Weighted median	Estimate		0.29 (0.14, 0.45)	<0.001		0.20 (0.07, 0.34)	0.003
2	HbA1c	LDL cholesterol	IVW	Estimate	11	0.23 (0.05, 0.41)	0.015	10	0.15 (−0.31, 0.61)	0.521
			MR Egger	Intercept		−0.01 (−0.03, 0.01)	0.281		−0.05 (−0.08, −0.01)	0.004
				Slope		0.45 (0.01, 0.88)	0.046		0.14 (0.39, 1.89)	0.003
			MR Egger (SIMEX)	Intercept		−0.01 (−0.02, 0.00)	0.053		0.00 (−0.02, 0.02)	0.780
				Slope		0.27 (0.11, 0.44)	0.007		0.16 (−0.33, 0.65)	0.539
			MR-PRESSO (O-C)	Estimate	10	0.14 (0.03, 0.25)	0.010	9	0.38 (0.03, 0.72)	0.032
			Weighted median	Estimate		0.15 (0.03, 0.26)	0.012		0.44 (0.03, 0.84)	0.036

MR, Mendelian randomization; IVW, inverse–variance–weighted; SIMEX, simulation extrapolation; PRESSO (O-C), Pleiotropy RESidual Sum and Outlier (outlier-correction); LDL, low-density lipoprotein; CAD, coronary artery disease; CI, confidence interval; FPG, fasting plasma glucose; Hb1Ac, hemoglobin A1c.

Table 6. Significant results from bidirectional MR analysis

No.	Exposure	Outcome	MR methods	parameter	N	Original study		N	Replication study	
						Estimate (95% CI)	P		Estimate (95% CI)	P
1	CAD	FPG	IVW	Estimate	30	0.00 (−0.02, 0.02)	0.873	83	0.00 (−0.01, 0.01)	0.834
			MR Egger	Intercept		0.00 (−0.01, 0.01)	0.352		0.00 (−0.01, 0.01)	0.813
				Slope		−0.02 (−0.06, 0.02)	0.437		0.00 (−0.02, 0.03)	0.906
			MR Egger (SIMEX)	Intercept	29	0.00 (−0.01, 0.01)	0.435		0.00 (−0.01, 0.01)	0.907
				Slope		0.01 (−0.01, 0.02)	0.781		0.00 (−0.01, 0.01)	0.844
			MR-PRESSO (O-C)	Estimate		0.00 (−0.02, 0.02)	0.877		No outlier	—
			Weighted median	Estimate		0.01 (−0.01, 0.03)	0.186		0.00 (−0.01, 0.01)	0.834
2	LDL cholesterol	HbA1c	IVW	Estimate	74	0.02 (−0.01, 0.05)	0.202	4	−0.01 (−0.04, 0.03)	0.681
			MR Egger	Intercept		0.00 (−0.01, 0.01)	0.263		0.00 (−0.02, 0.02)	0.796
				Slope		−0.01 (−0.06, 0.05)	0.859		−0.02 (−0.13, 0.09)	0.719
			MR Egger (SIMEX)	Intercept	71	0.02 (−0.01, 0.00)	0.056		0.00 (−0.01, 0.01)	0.513
				Slope		0.02 (−0.01, 0.05)	0.158		−0.02 (−0.03, 0.01)	0.548
			MR-PRESSO (O-C)	Estimate		0.02 (−0.01, 0.04)	0.234		Not enough IVs	—
			Weighted median	Estimate		−0.01 (−0.03, 0.03)	0.911		−0.02 (−0.04, 0.02)	0.376

MR, Mendelian randomization; IVW, inverse-variance-weighted; SIMEX, simulation extrapolation; PRESSO (O-C), Pleiotropy RESidual Sum and Outlier (outlier-correction); LDL, low-density lipoprotein; CAD, coronary artery disease; CI, confidence interval; FPG, fasting plasma glucose; Hb1Ac, hemoglobin A1c.

11 Figure Legends

Figure 1. Causal directed acyclic graph for MR analysis.

MR, Mendalian randomization.

Figure 2. Statistical power evaluations of MR analyses based on the T2D-diagnosis criteria. (A) FPG, (B) 2h-PG, and (C) HbA1c. We used a conservative significance threshold of $P < 0.007$ with Bonferroni correction using 7 of testing.


MR, Mendalian randomization; T2D, type 2 diabetes; FPG, fasting plasma glucose; 2h-PG, 2-h plasma glucose; HbA1c, hemoglobin A1c; OR, odds ratio; SD, standard deviation.




Figure 3. MR analysis of the effect of FPG on CAD. (A) Funnel plot displaying individual causal effect estimates for FPG on CAD. Dots representing the estimated causal effect for each IV. (B) The association between the effect size estimates on the FPG (X-axis) and CAD (Y-axis) for all SNPs that served as IVs.



FPG, fasting plasma glucose; CAD, coronary artery disease; IV, instrumental variable; SNP, single-nucleotide polymorphism; SIMEX, simulation extrapolation; PRESSO (O-C), Pleiotropy RESidual Sum and Outlier (outlier-correction).



Figure 4. MR analysis of the effect of HbA1c on LDL levels. (A) Funnel plot displaying individual causal effect estimates for HbA1c on LDL levels. Dots represent the estimated causal effect for each IV. (B) The relationship between the effect size estimates on HbA1c (X-axis) and LDL level (Y-axis) for all SNPs that served as IVs.

MR, Mendalian randomization; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein; IV, instrumental variable; SNP, single-nucleotide polymorphism; SIMEX, simulation extrapolation; PRESSO (O-C), Pleiotropy RESidual Sum and Outlier (outlier-correction).



Fasting Plasma Glucose**2hr Plasma Glucose****HbA1c**





Supplementary Material

Supplementary Table 1. Instrument variables for HbA1c and LDL cholesterol.

Chr	SNP	EA	OA	SNP Exposure			SNP Outcome		
				Beta	SE	P	Beta	SE	P
1	rs2779116	T	C	0.024	0.004	2.75	0.013	0.006	0.106
2	rs552976	G	A	0.029	0.003	8.16	0.002	0.004	0.424
6	rs1800562	A	G	-0.064	0.007	2.59	-0.062	0.008	4.42
7	rs1799884	T	C	0.038	0.004	1.45	-0.002	0.005	0.988
8	rs4737009	A	G	0.027	0.004	6.12	0.003	0.004	0.574
8	rs6474359	C	T	-0.060	0.011	1.18	-0.026	0.011	0.030
10	rs16926246	T	C	-0.089	0.006	3.11	-0.018	0.007	0.001
11	rs1387153	T	C	0.026	0.004	3.96	-0.003	0.004	0.490
13	rs7998202	G	A	0.031	0.005	5.24	-0.005	0.008	0.804
17	rs1046896	T	C	0.035	0.003	1.58	0.002	0.004	0.528
22	rs855791	G	A	-0.027	0.004	2.74	-0.010	0.004	0.003

Chr, chromosome; EA, effect allele; OA, other allele; SE, standard error; LDL, low-density lipoprotein; HbA1c, hemoglobin A1c; SNP, single-nucleotide polymorphism.

Supplementary Table 2. MR results for T2D-related traits on cancers and vascular disease.

Trait and MR methods	Parameter	N	FPG	P	N	2h-PG	P	N	HbA1c	P
			Estimate (95% CI)			Estimate (95% CI)			Estimate (95% CI)	
1. Cancer										
Breast cancer										
IVW	Estimate	34	−0.05 (−0.28, 0.18)	0.671	7	0.16 (−0.06, 0.37)	0.151	11	−0.01 (−0.28, 0.25)	0.922
MR-Egger	Intercept		0.00 (−0.01, 0.01)	0.537		−0.09 (−0.16, −0.01)	0.028		0.02 (0.00, 0.04)	0.067
	Slope		−0.18 (−0.65, 0.29)	0.456		1.08 (0.24, 1.92)	0.012		−0.46 (−0.98, 0.07)	0.092
MR-Egger (SIMEX)	Intercept		0.00 (−0.01, 0.01)	0.996		0.00 (−0.02, 0.03)	0.941		0.01 (−0.01, 0.02)	0.301
	Slope		−0.05 (−0.29, 0.19)	0.679		0.15 (−0.11, 0.42)	0.303		−0.04 (−0.30, 0.23)	0.800
MR-PRESSO (O-C)	Estimate	33	−0.10 (−0.32, 0.36)	0.364	5	0.16 (−0.01, 0.34)	0.068		No outlier	—
Weighted median	Estimate		−0.20 (−0.44, 0.04)	0.094		0.21 (0.06, 0.36)	0.008		−0.03 (−0.32, 0.29)	0.842
Lung cancer										
IVW	Estimate	33	0.05 (−0.22, 0.32)	0.721	7	−0.13 (−0.32, 0.06)	0.188	11	0.36 (−0.16, 0.88)	0.173
MR-Egger	Intercept		0.01 (−0.01, 0.02)	0.330		−0.06 (−0.15, 0.03)	0.182		0.04 (−0.01, 0.08)	0.102
	Slope		−0.17 (−0.68, 0.35)	0.523		0.48 (−0.43, 1.39)	0.301		−0.50 (−1.65, 0.64)	0.389
MR-Egger (SIMEX)	Intercept		−0.01 (−0.02, 0.01)	0.148		0.00 (−0.02, 0.03)	0.795		0.00 (−0.02, 0.02)	0.898
	Slope		0.14 (−0.19, 0.35)	0.351		−0.15 (−0.39, 0.09)	0.286		0.37 (−0.19, 0.94)	0.233
MR-PRESSO (O-C)	Estimate		No outlier	—		No outlier	—		No outlier	—
Weighted median	Estimate		−0.03 (−0.37, 0.32)	0.880		−0.08 (−0.32, 0.16)	0.494		0.04 (−0.47, 0.54)	0.886
SC lung cancer										
IVW	Estimate	33	0.39 (0.02, 0.76)	0.037	7	−0.19 (−0.46, 0.08)	0.161	11	0.36 (−0.16, 0.88)	0.173
MR-Egger	Intercept		0.00 (−0.02, 0.02)	0.792		0.00 (−0.13, 0.13)	0.968		0.04 (−0.01, 0.08)	0.102
	Slope		0.31 (−0.38, 1.00)	0.376		−0.17 (−1.52, 1.19)	0.811		−0.50 (−1.65, 0.64)	0.389
MR-Egger (SIMEX)	Intercept		0.00 (−0.01, 0.01)	0.480		0.01 (−0.01, 0.03)	0.307		−0.01 (−0.04, 0.02)	0.453
	Slope		0.41 (0.05, 0.77)	0.032		−0.26 (−0.46, −0.06)	0.052		0.58 (−0.09, 1.26)	0.127
MR-PRESSO (O-C)	Estimate		No outlier	—		No outlier	—		No outlier	—
Weighted median	Estimate		0.36 (−0.17, 0.88)	0.180		−0.16 (−0.50, 0.17)	0.341		0.04 (−0.47, 0.54)	0.886
Ovarian cancer										
IVW	Estimate	33	−0.14 (−0.68, 0.42)	0.632	7	0.14 (−0.29, 0.58)	0.526	11	0.16 (−0.73, 1.06)	0.719
MR-Egger	Intercept		0.08 (−0.96, 1.13)	0.882		−0.01 (−0.24, 0.21)	0.905		0.06 (−0.02, 0.13)	0.142
	Slope		−0.01 (−0.04, 0.02)	0.637		0.28 (−2.12, 2.69)	0.817		−1.19 (−3.18, 0.80)	0.242
MR-Egger (SIMEX)	Intercept		−0.01 (−0.02, 0.01)	0.426		−0.04 (−0.07, −0.01)	0.044		0.03 (0.00, 0.06)	0.089
	Slope		−0.11 (−0.66, 0.44)	0.705		0.39 (0.03, 0.75)	0.087		−0.03 (−0.85, 0.79)	0.948
MR-PRESSO (O-C)	Estimate		No outlier	—		No outlier	—		No outlier	—
Weighted median	Estimate		−0.46 (−1.33, 0.40)	0.293		−0.01 (−0.54, 0.53)	0.980		0.08 (−1.05, 1.21)	0.886
Pancreatic cancer										
IVW	Estimate	25	−0.14 (−1.07, 0.79)	0.768	6	−0.01 (−0.50, 0.49)	0.973	8	0.53 (−0.64, 1.71)	0.374

MR-Egger	Intercept		0.02 (−0.03, 0.06)	0.537		−0.04 (−0.27, 0.18)	0.702		0.03 (−0.08, 0.14)	0.592
	Slope		−0.64 (−2.49, 1.21)	0.497		0.45 (−1.94, 2.84)	0.713		−0.11 (−2.78, 2.56)	0.934
MR-Egger (SIMEX)	Intercept		−0.01 (−0.04, 0.02)	0.455		0.00 (−0.01, 0.05)	0.874		0.01 (−0.04, 0.06)	0.792
	Slope		−0.07 (−1.03, 0.89)	0.883		0.02 (−0.53, 0.57)	0.942		0.51 (−0.77, 1.79)	0.464
MR-PRESSO (O-C)	Estimate		No outlier	—		No outlier	—		No outlier	—
Weighted median	Estimate		−0.81 (−2.01, 0.38)	0.184		−0.05 (−0.67, 0.57)	0.883		0.46 (−0.87, 1.78)	0.500
Thyroid cancer										
IVW	Estimate	27	−0.34 (−1.67, 0.98)	0.612	5	−0.53 (−1.43, 0.38)	0.257	9	0.68 (−0.97, 2.33)	0.417
MR-Egger	Intercept		0.06 (−0.01, 0.13)	0.116		0.32 (−0.08, 0.73)	0.122		−0.07 (−0.21, 0.07)	0.349
	Slope		−1.89 (−4.22, 0.43)	0.110		−3.97 (−8.43, 0.49)	0.081		2.30 (−1.47, 6.07)	0.231
MR-Egger (SIMEX)	Intercept		0.00 (−0.05, 0.04)	0.918		0.06 (−0.04, 0.17)	0.333		−0.02 (−0.07, 0.02)	0.344
	Slope		−0.34 (−1.73, 1.05)	0.641		−0.98 (−2.12, 0.16)	0.192		0.89 (−0.30, 2.09)	0.186
MR-PRESSO (O-C)	Estimate		No outlier	—		No outlier	—		No outlier	—
Weighted median	Estimate		−1.14 (−2.73, 0.44)	0.157		−0.80 (−1.98, 0.38)	0.184		1.19 (−0.89, 3.28)	0.262
2. Cardiovascular disease										
CAD										
IVW	Estimate	34	0.21 (0.05, 0.37)	0.012	7	0.12 (−0.06, 0.31)	0.183	11	0.24 (0.02, 0.46)	0.031
MR-Egger	Intercept		0.00 (−0.01, 0.01)	0.530		0.05 (−0.03, 0.14)	0.231		0.02 (−0.01, 0.03)	0.078
	Slope		0.13 (−0.18, 0.43)	0.426		−0.42 (−1.32, 0.48)	0.365		−0.14 (−0.60, 0.33)	0.569
MR-Egger (SIMEX)	Intercept		0.00 (−0.01, 0.01)	0.443		0.00 (−0.02, 0.02)	0.833		0.00 (−0.01, 0.01)	0.762
	Slope		0.22 (0.06, 0.39)	0.014		0.14 (−0.09, 0.37)	0.301		0.23 (−0.01, 0.47)	0.085
MR-PRESSO (O-C)	Estimate	32	0.18 (0.01, 0.35)	0.045	5	0.21 (0.13, 0.29)	<0.001	10	0.19 (−0.01, 0.39)	0.069
Weighted median	Estimate		0.29 (0.14, 0.45)	<0.001		0.21 (0.10, 0.31)	<0.001		0.09 (−0.11, 0.30)	0.369
CKD										
IVW	Estimate	32	0.12 (−0.13, 0.36)	0.351	7	0.08 (−0.07, 0.23)	0.301	10	0.16 (−0.16, 0.47)	0.337
MR-Egger	Intercept		−0.01 (−0.02, 0.01)	0.281		0.01 (−0.06, 0.09)	0.760		−0.01 (−0.03, 0.02)	0.697
	Slope		0.33 (−0.13, 0.78)	0.159		−0.04 (−0.83, 0.75)	0.916		0.29 (−0.48, 1.07)	0.455
MR-Egger (SIMEX)	Intercept		0.01 (−0.01, 0.01)	0.109		0.01 (−0.01, 0.02)	0.555		0.00 (−0.01, 0.01)	0.785
	Slope		0.08 (−0.16, 0.32)	0.496		0.05 (−0.13, 0.23)	0.601		0.17 (−0.14, 0.49)	0.315
MR-PRESSO (O-C)	Estimate		No outlier	—		No outlier	—		No outlier	—
Weighted median	Estimate		0.17 (−0.12, 0.46)	0.252		0.09 (−0.10, 0.28)	0.359		0.24 (−0.17, 0.65)	0.243
HDL cholesterol										
IVW	Estimate	34	−0.08 (−0.08, 0.25)	0.320	7	0.07 (−0.08, 0.23)	0.342	11	0.19 (−0.11, 0.51)	0.206
MR-Egger	Intercept		0.01 (0.00, 0.02)	0.219		0.02 (−0.06, 0.09)	0.680		0.03 (0.00, 0.06)	0.049
	Slope		−0.08 (−0.39, 0.23)	0.606		−0.10 (−0.94, 0.74)	0.817		−0.37 (−1.01, 0.27)	0.252
MR-Egger (SIMEX)	Intercept		0.00 (−0.01, 0.01)	0.728		−0.01 (−0.03, 0.00)	0.064		0.01 (−0.01, 0.02)	0.227
	Slope		0.09 (−0.08, 0.26)	0.259		0.15 (0.02, 0.28)	0.074		0.17 (−0.12, 0.47)	0.282
MR-PRESSO (O-C)	Estimate	28	0.04 (−0.03, 0.09)	0.265	5	0.04 (−0.02, 0.11)	0.206		No outlier	—

Weighted median	Estimate		0.03 (−0.05, 0.10)	0.514		0.01 (−0.05, 0.06)	0.833		0.07 (−0.32, 0.46)	0.729
LDL cholesterol										
IVW	Estimate	34	0.02 (−0.16, 0.20)	0.807	7	0.04 (−0.11, 0.19)	0.626	11	0.23 (0.05, 0.41)	0.015
MR-Egger	Intercept		0.01 (−0.01, 0.01)	0.394		0.02 (−0.05, 0.09)	0.566		−0.01 (−0.03, 0.01)	0.281
	Slope		−0.10 (−0.44, 0.24)	0.551		−0.19 (−1.00, 0.61)	0.636		0.45 (0.01, 0.88)	0.046
MR-Egger (SIMEX)	Intercept		0.00 (−0.01, 0.01)	0.341		−0.01 (−0.03, 0.01)	0.143		−0.01 (−0.02, 0.00)	0.053
	Slope		0.04 (−0.14, 0.22)	0.695		0.10 (−0.05, 0.25)	0.241		0.27 (0.11, 0.44)	0.007
MR-PRESSO (O-C)	Estimate	27	0.04 (−0.03, 0.11)	0.225	5	0.06 (0.01, 0.11)	0.033	10	0.14 (0.03, 0.25)	0.010
Weighted median	Estimate		−0.01 (−0.08, 0.07)	0.890		0.04 (−0.02, 0.10)	0.214		0.15 (0.03, 0.26)	0.012
Stroke										
IVW	Estimate	34	0.15 (−0.03, 0.33)	0.104	7	0.06 (−0.06, 0.17)	0.338	11	−0.06 (−0.27, 0.15)	0.567
MR-Egger	Intercept		0.01 (0.00, 0.02)	0.005		−0.02 (−0.07, 0.04)	0.579		0.01 (−0.01, 0.03)	0.308
	Slope		−0.24 (−0.56, 0.08)	0.137		0.22 (−0.37, 0.81)	0.467		−0.30 (−0.81, 0.21)	0.244
MR-Egger (SIMEX)	Intercept		0.00 (−0.01, 0.01)	0.174		0.00 (−0.01, 0.01)	0.930		0.00 (−0.01, 0.01)	0.396
	Slope		0.17 (−0.01, 0.35)	0.078		0.06 (−0.09, 0.21)	0.469		−0.09 (−0.31, 0.13)	0.451
MR-PRESSO (O-C)	Estimate	33	0.13 (−0.04, 0.31)	0.135		0.05 (−0.06, 0.17)	0.338		No outlier	—
Weighted median	Estimate		0.02 (−0.16, 0.19)	0.835		0.04 (−0.08, 0.16)	0.506		−0.15 (−0.38, 0.08)	0.205
Stroke (cardio-embolic)										
IVW	Estimate	34	0.22 (−0.05, 0.48)	0.118	7	0.06 (−0.13, 0.26)	0.530	11	−0.51 (−0.94, −0.04)	0.023
MR-Egger	Intercept		0.01 (0.00, 0.03)	0.047		0.00 (−0.09, 0.09)	0.988		0.02 (−0.02, 0.06)	0.369
	Slope		−0.23 (−0.74, 0.29)	0.387		0.07 (−0.91, 1.05)	0.889		−0.93 (−1.96, 0.09)	0.076
MR-Egger (SIMEX)	Intercept		0.00 (−0.01, 0.01)	0.266		−0.01 (−0.02, 0.01)	0.383		0.01 (−0.01, 0.02)	0.403
	Slope		−0.03 (−0.03, 0.51)	0.094		0.11 (−0.07, 0.29)	0.294		−0.56 (−1.01, −0.10)	0.039
MR-PRESSO (O-C)	Estimate		No outlier	—		No outlier	—		No outlier	—
Weighted median	Estimate		0.03 (−0.36, 0.41)	0.889		0.01 (−0.24, 0.25)	0.937		−0.55 (−1.09, −0.02)	0.045
Stroke (small-vessel)										
IVW	Estimate	32	0.34 (0.04, 0.64)	0.025	7	0.16 (−0.02, 0.33)	0.084	10	0.37 (0.01, 0.73)	0.046
MR-Egger	Intercept		0.02 (0.01, 0.04)	0.016		0.03 (−0.05, 0.11)	0.443		−0.01 (−0.05, 0.02)	0.422
	Slope		−0.22 (−0.75, 0.32)	0.427		−0.16 (−1.00, 0.67)	0.700		0.71 (−0.19, 1.61)	0.124
MR-Egger (SIMEX)	Intercept		−0.01 (−0.01, 0.01)	0.209		0.00 (−0.02, 0.02)	0.744		0.00 (−0.02, 0.01)	0.551
	Slope		0.37 (0.08, 0.68)	0.020		0.11 (−0.07, 0.34)	0.255		0.42 (0.04, 0.79)	0.063
MR-PRESSO (O-C)	Estimate		No outlier	—		No outlier	—		No outlier	—
Weighted median	Estimate		0.16 (−0.24, 0.55)	0.435		0.12 (−0.10, 0.35)	0.294		0.46 (−0.03, 0.94)	0.065

MR, Mendelian randomization; T2D, type 2 diabetes; IVW, inverse-variance-weighted; SIMEX, simulation extrapolation; PRESSO (O-C), Pleiotropy RESidual Sum and Outlier (outlier-correction); SC, squamous cell; LDL, low-density lipoprotein; HDL, high-density lipoprotein; CKD, chronic kidney disease; CAD, coronary artery disease; CI, confidence interval; FPG, fasting plasma glucose; 2h-PG, 2-h plasma glucose; Hb1Ac, hemoglobin A1c.



Supplementary Table 3. Instrument variables for FPG and CAD.

Chr	SNP	EA	OA	SNP Exposure			SNP Outcome		
				Beta	SE	P	Beta	SE	P
1	rs17712208	A	T	0.051	0.007	3.22	0.002	0.019	0.920
2	rs1260326	C	T	0.029	0.002	2.17	-0.030	0.007	2.4×10^{-5}
2	rs479661	A	G	-0.019	0.003	8.56	-0.014	0.009	0.150
2	rs560887	C	T	0.071	0.003	1.40	0.023	0.008	0.002
3	rs11708067	G	A	-0.023	0.003	1.30	-0.020	0.008	0.017
3	rs11715915	T	C	-0.012	0.002	4.90	-0.021	0.008	0.005
3	rs1280	C	T	-0.026	0.003	8.56	0.007	0.010	0.520
3	rs7651090	G	A	0.013	0.002	1.75	0.033	0.007	1.2×10^{-5}
5	rs4869272	T	C	0.018	0.002	1.02	0.003	0.007	0.660
6	rs9368222	A	C	0.014	0.002	1.00	-0.005	0.008	0.560
7	rs17168486	T	C	0.031	0.003	3.17	-0.006	0.009	0.500
7	rs2191349	T	G	0.029	0.002	1.28	0.011	0.007	0.130
7	rs6943153	C	T	-0.015	0.002	1.63	0.005	0.007	0.500
7	rs6975024	C	T	0.061	0.003	2.88	0.027	0.009	0.003
7	rs882020	T	C	0.021	0.003	3.04	0.015	0.010	0.150
8	rs11558471	G	A	-0.029	0.002	7.80	-0.003	0.008	0.709
8	rs983309	G	T	-0.026	0.003	6.29	0.019	0.011	0.072
9	rs10811661	C	T	-0.024	0.003	5.65	-0.008	0.009	0.410
9	rs10814916	C	A	0.016	0.002	2.26	-0.010	0.007	0.130
9	rs16913693	G	T	-0.043	0.007	3.51	-0.004	0.021	0.830
9	rs3829109	A	G	-0.017	0.003	1.13	-0.025	0.008	0.002
10	rs11195502	T	C	-0.032	0.004	1.97	-0.023	0.012	0.048
10	rs7903146	T	C	0.022	0.002	2.71	0.017	0.008	0.027
11	rs10830963	G	C	0.078	0.003	1.00	0.007	0.008	0.370
11	rs11603334	A	G	-0.019	0.003	1.12	0.008	0.010	0.390
11	rs11607883	A	G	-0.021	0.002	6.32	0.000	0.007	0.960
11	rs174576	A	C	-0.020	0.002	1.18	-0.017	0.007	0.019
11	rs749067	C	T	-0.017	0.002	6.12	0.001	0.007	0.940
12	rs10747083	A	G	0.013	0.002	7.57	0.007	0.008	0.320
13	rs11619319	G	A	0.020	0.002	1.33	0.008	0.008	0.320
14	rs3783347	T	G	-0.017	0.003	1.32	-0.020	0.008	0.020
15	rs4502156	C	T	-0.022	0.002	1.38	0.001	0.007	0.890
20	rs6072275	A	G	0.016	0.003	1.66	-0.016	0.010	0.110
20	rs6113722	A	G	-0.035	0.005	2.49	-0.012	0.018	0.500

FPG, fasting plasma glucose; CAD, coronary artery disease; Chr, chromosome; EA, effect allele; OA, other allele; SE, standard error; LDL, low-density lipoprotein; HbA1c, hemoglobin A1c; SNP, single-nucleotide polymorphism.